Compare OPTU & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPTU | ASMB |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 567.7M | 512.1M |
| IPO Year | 2017 | 2010 |
| Metric | OPTU | ASMB |
|---|---|---|
| Price | $0.99 | $248.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $1.75 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 2.4M | 221.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,590,467,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $20.23 |
| 52 Week High | $2.14 | $39.71 |
| Indicator | OPTU | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 73.33 |
| Support Level | $0.81 | $25.86 |
| Resistance Level | $0.91 | $39.17 |
| Average True Range (ATR) | 0.08 | 1.79 |
| MACD | 0.02 | 0.79 |
| Stochastic Oscillator | 67.13 | 97.91 |
Optimum's assets were brought together when Altice Europe acquired US cable companies Suddenlink in 2015 and Cablevision in 2016. The Suddenlink business, which management calls the "West," provides television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. The Cablevision portion, dubbed the "East," provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Optimum, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.